GIGA-2339

Phase 1Small molecule

GGigaGen, Inc.

GIGA-2339 is one of 58 small molecule programs targeting Hepatitis B Virus Infection. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis B Virus InfectionRecruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Hepatitis B Virus InfectionPhase 1

Recruiting

Chronic Hepatitis B Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

82 competitors in Chronic Hepatitis B Virus Infection

#DrugCompanyPhaseTrials

Viread

GSK

Phase 3

1 2

Tyzeka

Novartis

Phase 3

1 3

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 4

PEG-Intron

Hepsera

Levovir

BBukwang Pharmaceutical

Viread

4 8

Vemlidy

Gilead

Phase 2

3 9

Imfinzi

Opdivo

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Hepatitis B Virus Infection

NCT07024641

Clinical

Trials by Indication[1]

Hepatitis B Virus Infection1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection

Recruiting·GGigaGen, Inc.·Phase 1·NCT07024641·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GIGA-2339. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GIGA-2339 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GIGA-2339. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GigaGen, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGigaGen, Inc.

GIGA-2339

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hepatitis B Virus Infection1 trial

References

Drug Info

Quick Facts

Related News